Home › Ventricular Tachycardia › NCT06138873
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy (AIM-VT) - a Prospective Single-Blinded, Multicenter Randomized Controlled Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patient ≥ 18 y.o. * Structural Heart Disease: Ischemic Cardiomyopathy * Sustained Scar-related Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation Exclusion Criteria: * If clinical ventricular arrhythmia is predominantly PVCs, supraventricular tachycardia, or ventricular fibrillation * Myocardial infarction or cardiac surgery within 6 months * Severe mitral regurgitation * Stroke or TIA within 6 months * Prior VT substrate ablation in the previous 6 months * NYHA functional class IV * Non-ischemic VT substrate
About the study
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.
What is being tested
- Ablation-index guided ventricular tachycardia ablation (procedure)
- Ventricular tachycardia ablation with no AI-guidance (procedure)
Sponsor: Rush University Medical Center · Participants: 100 · Started: Oct 23, 2024
Contact the study team
- Alexander Mazur, MD · Phone: 312-942-5020
Official record on ClinicalTrials.gov — NCT06138873
Locations in the U.S.
| Illinois | Rush University Medical Center, Chicago |
| Massachusetts | Mass General Brigham and Women's Hospital, Boston (Not yet recruiting) |
| Michigan | Medical University of Michigan, Ann Arbor (Not yet recruiting) |
| Minnesota | Mayo Clinic, Rochester (Not yet recruiting) |
| South Carolina | Medical University of South Carolina, Charleston (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.